University of Health Sciences, Ankara Oncology Training and Research Hospital, Department of Hematology and Bone Marrow Transplantation Center, Ankara, Turkey; Ankara Yıldırım Beyazıt University, School of Medicine, Department of Hematology, Ankara, Turkey.
Republic of Turkey, Ministry of Health, Department of Strategy Development, Ankara, Turkey.
Transfus Apher Sci. 2021 Feb;60(1):102955. doi: 10.1016/j.transci.2020.102955. Epub 2020 Sep 19.
Passive antibody therapy has been used to immunize vulnerable people against infectious agents. In this study, we aim to investigate the efficacy of convalescent plasma (CP) in the treatment of severe and critically ill patients diagnosed with COVID-19.
The data of severe or critically ill COVID-19 patients who received anti-SARS-CoV-2 antibody-containing CP along with the antiviral treatment (n = 888) and an age-gender, comorbidity, and other COVID-19 treatments matched severe or critically ill COVID-19 patients at 1:1 ratio (n = 888) were analyzed retrospectively.
Duration in the intensive care unit (ICU), the rate of mechanical ventilation (MV) support and vasopressor support were lower in CP group compared with the control group (p = 0.001, p = 0.02, p = 0.001, respectively). The case fatality rate (CFR) was 24.7 % in the CP group, and it was 27.7 % in the control group. Administration of CP 20 days after the COVID-19 diagnosis or COVID-19 related symptoms were associated with a higher rate of MV support compared with the first 3 interval groups (≤5 days, 6-10 days, 11-15 days) (p=0.001).
CP therapy seems to be effective for a better course of COVID-19 in severe and critically ill patients.
被动抗体疗法已被用于使易感染人群对感染因子产生免疫。在这项研究中，我们旨在研究恢复期血浆（CP）在治疗诊断为 COVID-19 的重症和危重症患者中的疗效。
回顾性分析了接受含抗 SARS-CoV-2 抗体 CP 联合抗病毒治疗的 888 例重症或危重症 COVID-19 患者（CP 组）和按年龄、性别、合并症和其他 COVID-19 治疗以 1:1 比例匹配的 888 例重症或危重症 COVID-19 患者的临床数据。
CP 组 ICU 住院时间、机械通气（MV）支持率和血管加压素支持率低于对照组（p = 0.001、p = 0.02、p = 0.001）。CP 组病死率（CFR）为 24.7%，对照组为 27.7%。CP 治疗在 COVID-19 诊断或 COVID-19 相关症状后 20 天给药与前 3 个间隔组（≤5 天、6-10 天、11-15 天）相比，MV 支持率更高（p=0.001）。
CP 治疗似乎对重症和危重症 COVID-19 患者的疾病进程有益。
